Headlands Research Portland site marks 50 years of continuous Alzheimer's trials, contributing to every FDA-approved ...
Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety ...
Advarra's IRB chief targets pre-review delays as the next efficiency frontier to reduce waiting time for researchers and trial participants.
First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, ...
A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how ...
Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled ...
Symphony RCT shows 55% closure rate in diabetic foot ulcers at 12 weeks, outperforming standard care alone with faster ...
VenaSeal cyanoacrylate closure healed 88% of venous leg ulcers with 92-day median healing time in 24-month study of excluded ...
Tekton Research's St. Louis site exceeded its enrollment goal in an Alzheimer's trial despite joining mid-stream as a rescue site.
AnnJi advances AJ201 into Phase 3 trial for Kennedy's disease, targeting 200 ambulatory patients globally with a potential ...
Niia Signature Patch achieves 20-minute glucose signal recovery after insulin bolus, addressing a key challenge in all-in-one ...
DHHS 2026 Unified Agenda proposes five clinical research rule changes affecting Phase 1 INDs, single IRB requirements, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results